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Abstract
Background: To evaluate whether infrared (IR) imaging findings are associated with prognosis in patients with
invasive breast carcinomas.
Methods: This study was approved by the institutional review board of the research ethics committee of our hospital,
and all participants gave written informed consent. From March 2005 to June 2007, we enrolled 143 patients with
invasive breast cancer that underwent preoperative IR imaging. We used five IR signs to interpret breast IR imaging.
Cox proportional hazards model was used to evaluate the effect of IR signs on long-term mortality.
Results: During a median follow-up of 2451 days (6.7 years), 31 patients died. Based on the Cox Proportional Hazards
Model, IR1 sign (the temperature of cancer site minus that of the contralateral mirror imaging site) was positively
associated with mortality in the univariate analysis (overall mortality hazard ratio [HR], 2.29; p = 0.03; disease-specific
mortality HR, 2.57; p = 0.04) as well as the multivariate analysis after controlling for clinicopathological factors (overall
mortality HR, 3.85; p = 0.01; disease-specific mortality HR, 3.91, p = 0.02). In patients with clinical stage I and II disease,
IR1 was also positively associated with mortality (overall mortality HR, 3.76; p = 0.03; disease-specific mortality HR, 4.59;
p = 0.03). Among patients with node-negative disease, IR1 and IR5 (asymmetrical thermographic pattern) were
associated with mortality (p = 0.04 for both IR1 and IR5, chi-squared test).
Conclusion: Breast IR findings are associated with mortality in patients with invasive breast carcinomas. The association
remained in patients with node-negative disease.
Trial registration: NCT00166998.
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Background
Infrared (IR) imaging of the breast, or breast thermog-
raphy, is a noninvasive modality that measures the
surface temperature of the breasts [1–3]. The localized
blood flow and metabolic activity of breast cancer are
higher than those in normal breast tissue, therefore, the
surface temperature overlying the breast cancer is
increased [1–3]. Nonetheless, IR imaging has been disre-
garded in the past due to several concerns including a lack
of a standardized protocol, technical difficulties, subjective
interpretation, suboptimal sensitivity and specificity for
lesion diagnosis, and no direct aid for spatial localization
for surgical removal of a tumor [2–7]. However, several
studies found that IR imaging was a valuable modality for
predicting the risk of breast cancer development and
survival [8–20]. In addition, abnormal thermography was
associated with advanced tumor staging and metastasis to
the lymph nodes [17, 19]. Recently, digital breast IR
imaging has resurfaced as an adjunct to mammography in
diagnosing breast cancer, especially in dense breast tissue
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[21, 22]. Moreover, some integrated interpretive models
using several different IR signs were also developed [2, 21,
23]. Digital IR was also reported to be associated with
prognosis in breast cancer patients [2, 22, 24–27]. Ohsumi
et al. [22] reported that increased mean temperature (ΔT >
= 0.9 °C) of the tumor area in comparison to that of the
corresponding area of the contralateral breast was an inde-
pendent significant prognostic factor for disease-specific
survival. However, they also reported that ΔT did not have
any prognostic impact on the patients with node-negative
disease [22]. Wang et al. [23] reported that breast IR signs
were related to molecular subtypes, clinical staging and
histologic grade of breast cancer, however, the analysis of
survival was not performed in this study.
In our current study, we evaluated the prognostic
value of breast IR imaging by five IR signs (Table 1). In
addition, we also evaluated the prognostic value of IR
imaging signs in patients with node-negative disease and
patients with stage I or II breast cancer, which was pre-
viously reported to be statistically insignificant [22].
Methods
Patient enrollment
From March 2005 to June 2007, we enrolled 143
patients with pathologically proven invasive breast car-
cinoma, and all of them underwent breast IR imaging
before operation. Those who received neoadjuvant
chemotherapy (NAC) before operation were excluded
from our study because the breast IR was performed
only at pre-treatment stage, and the disease status after
NAC would change and cannot be comparable with that
of pre-treatment IR. The study participants were a
subgroup of the patients in our previous studies [2, 23],
one of which investigated the diagnostic performance of
different IR signs (298 lesions from 276 women, includ-
ing 174 breast cancer lesions from 165 patients) [2], and
the other prior study dealt with the assessment of the
association of IR signs with molecular subtypes of breast
cancer, including Estrogen Receptor, Progesterone
Receptor, and Human Epidermal Growth Factor Recep-
tor 2 in 171 breast cancer lesions from 163 patients [23].
In our current study, we report on the role of IR signs in
predicting the prognosis in women with invasive breast
carcinomas. This study was approved by the institutional
review board of the research ethics committee of our
hospital, and all participants gave written informed con-
sent before the IR examination.
IR imaging protocol and interpretation
The IR procedure, image processing, and interpretation
were conducted as previously described [2, 23]. The IR
imaging of the breast was performed using the ATIR-
M301 Thermal Imaging System (response wavelength of 8
to 12 mm; Associated Technology Corporation, Chong-
qing, Sichuan, China). The examination room was main-
tained at a constant temperature of 23 °C to 25 °C. Each
participant removed their upper outer garment and then
sat on a chair for 15 min, and the IR images were then
taken. The post-processing of IR images was performed
using M301-APP-V2.0 software (Associated Technology
Corporation). The location and size of the lesions were
marked by a radiologist (first radiologist) based on the
mammography and ultrasound studies and were then
recorded on a sheet. The other two radiologists (second
and third radiologists) interpreted the IR images, and their
interpretation was based only on the information from the
previously recorded sheet. The two IR imaging readers
were blinded to the detailed mammographic and ultra-
sonographic findings, pathologic results of the patients,
and the two radiologists were both specialized in breast
imaging for more than 10 years.
The five IR signs we used in this study (Table 1) were
modified from those described in the literature [2, 21, 23].
Besides, because of insignificant prognostic impact of ΔT in
node-negative patients as previously reported (ΔT> =0.9 °C
temperature difference of both breasts) [22], we adjusted
the positive IR1 sign as >2 °C difference in the temperature
(ΔT) of the lesion site from that of the contralateral breast.
Table 1 Descriptions of infrared (IR) imaging signs
Parameter Description of sign
IR1 Temperature difference (ΔT) of the lesion site from the mirror image site of
the contralateral breast. IR1 = 0 (negative) when ΔT≤ 2 °C; IR1 = 1
(positive) when ΔT > 2 °C.
IR2 Temperature difference of the lesion site from the adjacent normal breast.
IR2 = 0 (negative) when ΔT≤ 1 °C; IR2 = 1 (positive) when ΔT > 1 °C.
IR3 Abnormal vascular morphologic patterns at and around the tumor.
IR3 = 0 when the sign is absent; IR3 = 1 when the sign is present.
IR4 Focal edge or bulge of the surface contour with increased temperature.
IR4 = 0 when the sign is absent; IR4 = 1 when the sign is present.
IR5 Asymmetric thermographic and vascular patterns at the tumor site.
IR5 = 0 when the sign is absent; IR5 = 1 when the sign is present.
The table content was reprinted with permission and adapted from Wang et al., BioMedical Engineering OnLine 2010; 9:3. Doi:10.1186/1475-925X-9-3
(Publisher: BioMed Central Ltd, part of Springer Science + Business Medica) [2], and Wang et al., Academic Radiology 2011; 18(2): 212–219 (Publisher: Elsevier) [23]
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Survival analysis
All data were analyzed using IBM SPSS Statistics software,
version 21 (IBM SPSS Statistics for Windows, Version
21.0. Armonk, NY: IBM Corp.). The primary outcomes
were overall mortality and disease-specific mortality. The
follow-up period was defined as starting at the diagnosis
of breast cancer and ending on the date of death, the date
they were last known to be living, or the date of the most
recent follow-up. The last date of data collection was
December 31, 2014, and patients for whom no event had
occurred or who were lost to follow-up were censored
accordingly. The clinical follow-up and survival data of all
patients were retrieved from Cancer Registry, Cancer
Administration and Coordination Center of our hospital.
The univariate Cox proportional hazards model was
used to analyze the association of the five IR signs (IR1 to
IR5) and the clinicopathological variables (age, meno-
pausal status, clinical stage, histologic type, nuclear grad-
ing, and molecular subtypes) with overall mortality and
disease-specific mortality. A multivariate Cox proportional
hazards model was also used to analyze the correlation of
the IR signs with overall mortality and disease-specific
mortality after adjusting for the clinicopathological vari-
ables. The association between the IR signs and overall
survival in patients with node-negative and node-
positive disease was evaluated using the chi-squared
test. P values < 0.05 were considered to indicate statis-
tical significance.
The overall and disease-specific survivals were esti-
mated using the Kaplan-Meier method. The log-rank
test was used to compare the survival curves between
groups categorized by different IR signs.
Results
In total, 143 patients with primary invasive breast cancer
were enrolled in this study (age range, 27–81 years; mean
age, 54.2 years). Table 2 summarizes the clinical data of
the patients. Of them, 101 (70.6 %) patients had stage I
and II disease, and just over half of the patients (78/143,
54.5 %) had the luminal molecular subtype. As for the
histologic type, 130 patients (90.9 %) had invasive ductal
carcinomas, eight patients (5.6 %) had invasive lobular
carcinomas, and five patients (3.5 %) had other histologic
types of carcinoma. Of the 143 patients, 136 (95 %) had
unilateral breast disease and seven of them (5 %) had
bilateral synchronous breast cancers. All the patients
underwent definitive surgery followed by appropriate
adjuvant therapy including chemotherapy, hormone
therapy, or targeted therapy, radiotherapy according to
National Comprehensive Cancer Network (NCCN®)
guidelines (Fort Washington, PA, USA) for breast cancer.
The median follow-up period for all of the patients
was 2451 days (6.7 years; range, 172–2920 days). During
this period, 31 (22 %) patients died. Among the deceased
patients, 28 (90.3 %) died of breast cancer, and three
died due to other unrelated disorders (one of pancrea-
titis, another of liver cirrhosis, and the etiology of the
death of the remaining patients was undetermined).
Survival analysis
For the univariate analysis, a high clinical stage was
associated with poor survival (overall mortality hazard
ratio [HR]: 1 [stages I and II], 3.00 [stage III], 10.89
[stage IV], p < 0.0001; disease-specific mortality HR: 1
[stages I and II], 1.92 [stage III], 14.02 [stage IV]; p <
0.0001). Age, menopausal status, histological grade,
pathologic type, and molecular subtype were not signifi-
cantly associated with mortality. The univariate analysis
of the IR signs revealed that a positive IR1 (ΔT > 2 °C)
was associated with poor survival (overall mortality HR,
2.29; p = 0.03; disease-specific mortality HR, 2.57; p =
0.04). Other IR factors were not significantly associated
with mortality in univariate analysis (Table 3).
In the multivariate analysis of IR signs, controlling for
clinicopathological factors (including age, clinical tumor





Bilateral breast cancer 7 (5)
Clinical stage
Stage I and II 101 (70.6)
Stage III 31 (21.7)
Stage IV 11 (7.7)
Molecular subtype
ER/PR-positive, HER2-negative 78 (54.5)
HER2-positive 32 (22.4)
Triple negative 33 (23.1)
Histology types
Invasive ductal carcinoma 130 (90.9)
Grade 1 15 (10.5)
Grade 2 68 (47.5)
Grade 3 39 (27.3)
Unknown 8 (5.6)
Other cancer types
Invasive lobular carcinoma 8 (5.6)
Apocrine carcinoma 1 (0.7)
Mucinous carcinoma 1 (0.7)
Intracystic papillary carcinoma 2 (1.4)
Metaplastic carcinoma 1 (0.7)
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal
growth factor receptor 2
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stage, pathological tumor grade, molecular subtype), a
positive IR1 sign was associated with poor survival out-
come (overall mortality HR, 3.85; p = 0.01; disease-
specific mortality HR, 3.91; p = 0.02). The other IR signs
were not significantly related to survival outcome
(Table 4).
Among the 101 patients with stage I or II breast can-
cer, a positive IR1 sign was also associated with poor
survival (overall mortality HR, 3.76; p = 0.03; disease-
specific mortality HR, 4.59; p = 0.03). Other IR factors
were not significantly associated with survival outcome
(Table 5). Among patients with advanced stage breast
Table 3 Univariate analysis of overall mortality and disease-specific mortality
Overall mortality Disease-specific mortality
Variable n HR 95 % CI p HR 95 % CI p
Age≤ 50 years 51 1 0.92 1 0.45
Age > 50 years 92 0.96 0.44–2.08 1.49 0.54–4.12
Postmenopausal 85 1.06 0.50–2.27 0.87 0.94 0.38–2.34 0.89
Clinical stage <0 .0001 <0.0001
stages I & II 101 1 1
Stage III 31 3.00 1.24–7.24 1.92 0.58–6.39
Stage IV 11 10.89 4.35–27.23 14.02 5.05–38.94
Histology 0.14 0.92
IDC 130 1 1
ILC 8 2.94 1.02–8.51 1.06 0.14–7.99
Other subtypes 5 1.07 0.14–7.95 1.51 0.20–11.35
IDC tumor grade 0.80 0.86
Grade 1 15 1 1
Grade 2 68 1.84 0.23–14.71 0.58 0.32–1.04
Grade 3 39 2.10 0.25–17.96 0.40 0.21–0.79
Molecular subtype 0.39 0.36
Luminal 78 1 1
HER2-enriched 32 1.73 0.71–4.24 0.87 0.23–3.22
Triple-negative 33 1.65 0.67–4.03 1.90 0.71–5.11
IR signs a
IR1 0.03 0.04
IR1 = 0 109 1 1
IR1 = 1 34 2.29 1.07–4.89 2.57 1.03–6.40
IR2 0.75 0.42
IR2 = 0 61 1 1
IR2 = 1 82 0.89 0.42–1.87 0.69 0.28–1.70
IR 3 0.33 0.53
IR3 = 0 12 1 1
IR3 = 1 131 2.71 0.37–19.95 1.91 0.26–14.34
IR 4 0.50 0.22
IR4 = 0 114 1 1
IR4 = 1 29 1.34 0.57–3.16 1.83 0.70–4.81
IR 5 0.47 0.93
IR5 = 0 26 1 1
IR5 = 1 117 1.48 0.51–4.27 0.95 0.32–2.87
Estimated by univariate Cox proportional hazards analysis
HR hazard ratio, 95 % CI 95 % confidence interval, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma; IR: infrared
aIR imaging signs are defined in Table 1; 0 = negative, 1 = positive
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cancer (clinical stage III or IV, n = 42), no IR sign was
significantly associated with overall or disease-specific
survival outcomes.
There were 69 node-positive and 74 node-negative
patients. Among the 74 patients with node-negative
disease, the positive IR1 (ΔT > 2 °C) and IR5 signs
(asymmetric thermographic pattern) were associated
with high overall mortality (p = 0.04 for both IR1 and
IR5, chi-squared test). The other IR signs showed no
significant relation to mortality (Table 6). On the other
hand, among node-positive patients (n = 69), there was
no significant association of IR signs and overall mortal-
ity (IR1, IR2, IR3, IR4, and IR5, p = 0.77, 0.08, 0.74, 0.41,
and 0.05, respectively, chi-square test).
Kaplan-Meier analysis showed that the IR1-positive
patients had poorer overall and disease-specific survival
rates than the IR1-negative patients (log-rank test, p =
0.028 and 0.005 for overall and disease-specific survival,
respectively) (Figs. 1 and 2).
Discussion
We evaluated the association of breast IR signs with
survival outcomes. We found that a positive IR1 sign was
significantly associated with higher mortality. In addition,
Table 4 Association of IR signs and overall mortality and
disease-specific mortality after controlling for clinicopathological
variables
Overall mortality Disease-specific mortality
Variable n HR 95 % CI p HR 95 % CI p
IR parametera
IR1 0.01 0.02
IR1 = 0 109 1 1
IR1 = 1 34 3.85 1.37–10.81 3.91 1.22–12.59
IR2 0.65 0.30
IR2 = 0 61 1 1
IR2 = 1 82 0.80 0.30–2.15 0.56 0.18–1.68
IR3 0.88 0.93
IR3 = 0 12 1 1
IR3 = 1 131 0.85 0.10–6.96 1.11 0.13–9.44
IR4 0.98 0.16
IR4 = 0 114 1 1
IR4 = 1 29 1.01 0.33–3.10 2.26 0.74–6.93
IR5 0.85 0.60
IR5 = 0 26 1 1
IR5 = 1 117 1.14 0.31–4.17 0.69 0.18–2.66
Estimated by multivariate Cox proportional hazards model
Clinicopathological variables: age, clinical tumor staging, pathological tumor
grade, molecular subtypes
HR hazard ratio, 95 % CI 95 % confidence interval
aIR imaging signs are defined in Table 1; 0 = negative, 1 = positive
Table 5 Association of IR findings with mortality in patients
with clinical stage I and II tumors
Variable Overall mortality Disease-specific mortality
n HR 95 % CI p HR 95 % CI p
IR signsa
IR1 0.03 0.03
IR1 = 0 81 1 1
IR1 = 1 20 3.76 1.15–12.31 4.59 1.15–18.37
IR2 0.93 0.62
IR2 = 0 46 1 1
IR2 = 1 55 1.06 0.32–3.46 1.43 0.34–6.00
IR3 0.45 0.93
IR3 = 0 10 1 1
IR3 = 1 91 0.68 0.45–1.68 0.92 0.11–7.45
IR4 0.94 0.22
IR4 = 0 83 1 1
IR4 = 1 18 0.95 0.20–4.39 2.45 0.58–10.25
IR5 0.72 0.53
IR5 = 0 19 1 1
IR5 = 1 82 0.91 0.55–1.51 1.96 0.24–15.95
Total number of patients with clinical stage I and II tumors = 101
Estimated by Cox proportional hazards model
HR hazard ratio, 95 % CI 95 % confidence interval
aIR imaging signs are defined in Table 1; 0 = negative, 1 = positive
Table 6 Prognostic significance of infrared (IR) imaging
parameters in patients with node-negative breast cancer
Deceased Survived
IR signsa n (%) n (%) p
IR1 0.04
IR1 = 0 7 52
IR1 = 1 5 10
IR2 0.60
IR2 = 0 5 31
IR2 = 1 7 31
IR3 0.26
IR3 = 0 0 6
IR3 = 1 12 56
IR4 0.96
IR4 = 0 10 52
IR4 = 1 2 10
IR5 0.04
IR5 = 0 0 17
IR5 = 1 12 45
Total number of patients with node-negative breast cancer = 74
The number of deceased patients = 12
Estimated by chi-square test
aIR imaging signs are defined in Table 1
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after adjusting for clinicopathological variables, the IR1 sign
was still a significant independent prognostic factor.
We found that a positive IR1 sign was related to
higher overall and disease- specific mortality in patients
with stage I and II cancers, and a positive IR1 sign was
associated with higher overall mortality in node-negative
patients. These findings differed from those of Ohsumi
et al. [22], since they found that an abnormal thermo-
gram did not have a prognostic impact on node-negative
patients [22]. The different results may be related to the
reasons below: first, the cutoff values of ΔT between the
two studies were different, that is, ΔT > 2 °C (for IR1
sign) in our study versus ΔT > = 0.9 °C in their study;
second, we used a staging system incorporating tumor
size (T), nodal status (N) and metastasis (M) as one of
the clinicopathological variables, while the Ohsumi’s
study analyzed tumor size, nodal status separately.
IR signs were not associated with survival outcomes in
women with stage III or IV breast cancer or in node-
positive patients in our study. The prognosis of these
patients is mainly related to the status of lymph node
metastasis or systemic metastasis, which may not have
been well evaluated in IR imaging since small lymph
nodes metastasis or visceral organ metastasis may not
show detectable surface temperature changes. In
addition, the abnormal lymph nodes deeper to pectoral
muscles are hard to be detected by IR. Although several
previous studies stated that patients with abnormal
thermograms had significantly larger tumors and higher
percentage of metastatic lymph nodes than patients with
normal thermograms, there was still no proof of the
prognostic value of thermography in the patients with
advanced breast cancer [17, 19, 22].
On the other hand, we found an asymmetric thermo-
graphic pattern (positive IR5 sign) was related to the higher
overall mortality in the patients without lymph node metas-
tasis. This was not surprising since an asymmetric thermo-
graphic pattern is a morphologically descriptive sign that
may reflect asymmetric surface temperatures [2], and thus
IR5 has a similar implication to IR1 sign. Therefore, breast
IR signs can be potential imaging markers to predict prog-
nosis in selected subgroups of breast cancer patients, that
is, patients with stage I, II cancers or node-negative patients
as stated above.
There are some limitations in this study. The sample
size was limited; therefore, we did not further stratify the
molecular subtypes in more detail. In addition, the treat-
ment protocols were heterogeneous due to different
molecular subtypes and stages, which may influence
survival. We did not include patients that underwent
neoadjuvant chemotherapy and we were not able to
perform serial breast IR studies to monitor treatment
response of neoadjuvant chemotherapy. Finally, we did
not compare the IR imaging to other diagnostic modal-
ities, such as mammography, ultrasound, MRI, or PET.
Conclusions
IR1 imaging sign could be a potential imaging marker to
predict prognosis in patients with invasive breast cancers
with stage I, II or node-negative disease. IR5 sign was
Fig. 1 Overall survival by IR1 sign in the Kaplan-Meier analysis.
The patients with a positive IR1 sign had significantly poorer overall
survival than patients with a negative IR1 sign (p = 0.028, log-rank test)
Fig. 2 Disease-specific survival by IR1 sign in the Kaplan-Meier
analysis. The patients with a positive IR1 sign had significantly poorer
disease-specific survival than patients with a negative IR1 sign (p= 0.005,
log-rank test)
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associated with overall mortality in breast cancer
patients with node-negative disease. In the future,
recruitment of more study participants to validate our
results, and use of IR to monitor treatment response for
patients with neoadjuvant chemotherapy are needed.
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